Misonix Product Featured At Neurosurgery Congress
FARMINGDALE, N.Y., Aug. 28, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced its participation in the 43rd Annual Meeting of the Argentinian Association of Neurosurgery, which was held recently in Buenos Aires, Argentina.
The Argentinian Association of Neurosurgery, with more than 500 members, is committed to physician education and to supporting research within its membership. Close to 300 delegates attended the Annual Meeting.
In addition to exhibiting and demonstrating its BoneScalpel™ product platform, the Company benefited from a workshop on the use of the BoneScalpel in advanced spine surgery, which was conducted by a German guest speaker, Dr. Daniel Rosenthal, Director of Spine Surgery at the Bad Homburg Regional Hospital in Frankfurt, Germany. Among other comments, Dr. Rosenthal, who was born in Argentina, noted the precise nature of the bone cuts, minimal bone loss, reduced bleeding, reduction in procedure time and safety associated with the use of BoneScalpel.
To quote Dr. Rosenthal, "I use the BoneScalpel in arthrectomy or vertebrectomy, and to decompress the foramina. In my opinion, it replaces the saw or drill in spine surgery."
In addition, two separate clinical poster sessions were presented by Dr. Juan P. Garraham, neurosurgeon at the National Children's Hospital, documenting his clinical success with BoneScalpel when used in deformity procedures such as scoliosis of the spine.
The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps. To date, reported uses of the Product in spine surgery include laminectomy, laminotomy, laminoplasty, corpectomy, spinal deformity, foraminotomy, facetectomy and other procedures performed by orthopedic and neuro surgeons.
"We were pleased to participate in this educational event that brings together practitioners and researchers from throughout Argentina and neighboring countries," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Exhibiting our state-of-the-art technology at this prestigious gathering and having it supported by workshops and clinical support statements demonstrate our continuing commitment to providing products to the medical community that can provide meaningful benefits to patients."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.
More by this Source
Misonix, Inc. Announces First Quarter Fiscal Year 2014 Financial Results
Nov 07, 2013, 16:05 ET
Misonix Exhibits at the Annual Paradigm Medical Management Meeting
Oct 23, 2013, 07:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.